TIVDAK® FDA Approved: Targeting Tissue Factor in Cervical Cancer
Last reviewed: 14.06.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
On April 29, 2024, the US Food and Drug Administration (FDA) fully approved TIVDAK® (tisotumab vedotin) from Seagen Inc., which targets tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed during or after chemotherapy. This represents a significant breakthrough in cervical cancer therapy, highlighting the potential of antibody-drug conjugates (ADCs) in oncology.
Mechanism of action of TIVDAK
Tivdak is an ADC drug that targets TF, combining Genmab's anti-TF monoclonal antibody tisotumab with Seagen's ADC technology designed to target TF antigens on cancer cells and deliver the cytotoxic moiety MMAE directly to cancer cells. p>
Молекулярный механизм действия тисотумаба ведотина (https://doi.org/10.3390/ijms23073559)
TF: идеальная мишень для разработки ADC
Известно, что TF участвует в сигнальных путях опухолевого роста и ангиогенезе и чрезмерно экспрессируется у подавляющего большинства пациентов с раком шейки матки и многих других твердых опухолях. Его способность быстро интернализоваться при связывании с антителами и минимальное воздействие на нормальные процессы свертывания крови дополнительно повышают его пригодность для целенаправленной терапии рака.